51˶

'Not Your Grandparents' Marijuana': What We Heard This Week

— Quotable quotes heard by 51˶'s reporters

MedpageToday
A female reporter holding two microphones takes notes on a pad

"This is not your grandparents' marijuana anymore, and there's a decreased harm perception." -- Tucker Woods, DO, of Lenox Health Greenwich Village in New York City, on the increased use and potency of cannabis.

"It's hard to get anything done in Washington, D.C., these days, but we're optimistic this is something that can move forward." -- Bruce Scott, MD, president of the American Medical Association, discussing hopes for passage of the Prior Authorization Bill.

"I would not try to take anything by mouth to try to decongest your nose." -- Pieter Cohen, MD, of Cambridge Health Alliance in Massachusetts, on common over-the-counter cold and flu drugs.

"RFK might realize there's a lot of stuff you have to do as HHS secretary that isn't any fun." -- Rodney Whitlock, PhD, of the health policy consulting firm McDermott+, considering the possibility of Robert F. Kennedy Jr. leading the federal agency under a second Trump administration.

"AI in colonoscopy is a double-edged sword." -- Brennan Spiegel, MD, MSHS, of Cedars-Sinai in Los Angeles, on how artificial intelligence-assisted colonoscopy boosted the removal rate of benign lesions.

"It's kind of a low-hanging fruit, for sure." -- Cristina Baldassari, MD, of the Children's Hospital of the King's Daughters and Eastern Virginia Medical School in Norfolk, on the link between vitamin D deficiency and pediatric obstructive sleep apnea.

"It was nice to see adolescent bariatric surgery be an outstanding treatment option out to 10 years." -- Justin Ryder, PhD, of the Ann and Robert H. Lurie Children's Hospital of Chicago, finding surgical weight loss was durable for teens.

"It will likely be the first FDA-approved therapy specifically for treating patients with depression with insomnia." -- Andrew Krystal, MD, of the University of California San Francisco Weill Institute for Neurosciences, discussing positive phase III data for the investigational drug seltorexant.